Adult Acute Leukemia

Current Problems in Cancer

Volumn 21, Issue 1, 1997, Pages 1-64

  Cripe, Larry D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE DISEASE; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGE; BONE MARROW TRANSPLANTATION; HUMAN; MYELOID LEUKEMIA; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RECURRENT DISEASE; REMISSION; REVIEW;

ACUTE DISEASE; ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, PROMYELOCYTIC, ACUTE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION;

EID: 0030640060     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0147-0272(97)80006-2     Document Type: Article

References (200)

1. Bennett JM, Andersen JW, Cassileth PA. Long term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leuk Res 1991;15:223-7.
2. Preisler HD, Anderson K., Rai K, et al.The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Br J Haematol 1989;71:189-94.
3. Mandelli F, Annino L, Rotoli B. The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. Br J Haematol 1996;92:665-72.
4. WahlinA, Hornsten P, Jonsson H. Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy. Eur J Haematol 1991 ;46:240-7.
5. Berman E. Chemotherapy in acute myelogenous leukemia: high dose, higher expectations? J Clin Oncol 1995;13:1-4.
6. Arlin ZA, Feldman EJ, Finger L, et al. "Quality" remissions: a new target of induction therapy in acute leukemia and the next step in developing curative treatment. Semin Hematol 1991;28:44-7.
7. Kassirer JP. Incorporating patients' preferences into medical decisions. N Engl J Med 1994;330:1895-6.
8. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985;103:626-9.
9. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institutesponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-9.
10. Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British co-operative group. Ann Intern Med 1985;103:626-9.
11. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. BrJHaematol 1976;33:451-8.
12. Bennett JM, Catovsky D, Daniel M-T, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991 ;78:325-9.
13. Paietta E, Andersen J, Wiernik PH. A new approach to analyzing the utility of immunophenotyping for predicting clinical outcome in acute leukemia. Leukemia 1996;10:l-4.
14. Matutes E. Contribution of immunophenotype in the diagnosis and classification of haemopoietic malignancies. J Clin Pathol 1995;48:194-7.
15. Boban D, Sucic M, Markovic-Glamocak M, et al. Correlation of morphological FAB classification and immunophenotyping: value in recognition of morphological, cytochemical and immunological characteristics of mixed leukaemias. Eur J Cancer 1993;29A:1167-72.
16. Cuneo A, Michaux J-L, Ferrant A, et al. Correlation of cytogenetic patterns and clinicobiological features in adult acute myeloid leukemia expressing lymphoid markers. Blood 1992;79:720-7.
17. Mayer RJ, Davis RB, Schiffer ÇA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896-903.
18. Levine E, Bloomfield C. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992;19:47-84.
19. Quesnel B, Kantarjian H, Bjcrgaard J, Brault R Estey E. Therapy related acute myeloid leukemia with t(8:21 ). inv(16). and t(8:16): a report on 25 cases and review of the literature. J Clin Oncol 1993;11:2370-9.
20. Berger R. Bernheim A, Oehoa-Noguera ME, et al. Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: a study of 343 patients. Cancer Genet Cytogenet 1987:28:293-9.
21. Groupe Français de Cytogenetique Hematologique. Acute myelogenous leukemia with an 8;21 translocation. Cancer Genet Cytogenet 1990:44:169-79.
22. Bloomfield CD, Lawrence D, Arthur DC. Berg DT, Schiffer CA, Mayer RJ. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 1994:84: Ilia.
23. Larson RA, Williams SF. Le Beau MM, Bitter MA, Vardiman JW, Rowley JD. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood 1986:68:1242-9.
24. Plantier I, Lai JL. Wattel E, Bauters F, Fenaux P. Concise report. lnv( 16) may be one of the only 'favorable' factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up. Leuk Res 1994;18:885-8.
25. Ghaddar HM, Plunkett W, Kantarjian HM. et al. Long-term results following treatment of newly diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 1994;8:1269-74.
26. Thirman MJ, Gill HJ. Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11 q23 chromosomal translocations. N EnglJMed 1993:329:909-14.
27. Groupe Français de Cytogenetique Hematologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hématologie findings and outcome. A collaborative study of the Groupe Français de Cytogenetique Hematologique. Blood 1996;87:3135-42.
28. Annino L, Ferrari A, Cedrone M. et al. Adult Philadelphia chromosome-positive acute lymphoblastic leukemia: experience of treatments during a ten-year period. Leukemia 1994;8:664-7.
29. Campbell LJ, Michael PM, White JS, Matthews JP. Prognostic implications of karyotype in 159 newly diagnosed adult patients with acute lymphoblastic leukaemia. Blood 1995;86:173a.
30. Bradstock K. Matthews J. Benson E, Page F, Bishop.I. Prognostic value of immunophenotyping in acute myeloid leukemia. Blood 1994:84:1220-5.
31. Ball ED, Davis RB, Griffin JD, et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991 ;77:2242-50.
32. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995:85:2025-37.
33. Fiere D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 1993;11:1990-2001.
34. Boucheix C, David B, Sebban C, et al. Immunopheiiotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). Blood 1994;84:1603-12.
35. Boldt DH, Kopecky KJ, Head D, Gehly G, Radien JP. Appelbaum FR. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. Leukemia 1994:8:2118-26.
36. Campos L, Guyotat D, Archimbaud E.et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992:79:473-6.
37. Thomas X, Archimbaud E, Charrin C, Magaud J-P. Fiere D. CD34 expression is asso-ciated with major adverse prognostic factors in adult acute lymphoblastic leukemia. Leukemia 1995;9:249-53.
38. ListAF. Preclinical investigations of drug resistance. Curr Opin Oncol 1995;7:19-27.
39. Lacombe F, Belloc F, Dumain P, et al. Quantitation of resistance of leukemic cells to cytosine arabinoside from BrdUrd/DNA bivariate histograms. Cytometry 1992;13:730-8.
40. -cases. Blood 1995;86:2329-42.
41. Guerci A, Merlin JL, Missoum N, et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995;85:2147-53.
42. Preisler HD. Failure of remission induction in acute myelocytic leukemia. Med Pediatr Oncol 1978;4:275-6.
43. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Causes of initial remission induction failure in acute myelogenous leukemia. Blood 1982;60:309-15.
44. Berman E, Geller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991 ;77:1666-74.
45. Vogler W, Welez-Garcia E, Weiner R, et al. Phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 1992;10:1103-11.
46. Wiernik PH, Banks PLC, Case DC, Jr., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79:313-9.
47. Wheatley K. Meta-analysis of randomized trials of idarubicin (IDR) or mitoxantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukaemia (AML). Blood 1995;86:434a.
48. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Blood 1990;75:27-32.
49. Schiller G, Gajewski J, Nimer S, et al. A randomized study of intermediate- versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. BrJHaematol 1992;81:170-7.
50. Weick J, Kpecky K, Appelbaum F, et al. A randomized investigation of high-dose (HDAC) versus standard dose (SDAC) cytosine arabinoside with daunorubicin (DNR) in patients with acute myelogenous leukemia. Proc ASCO 1992;11:261.
51. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-7.
52. Hiddemann W, Fonatsch C, Wormann B, et al. Cytogenetic subgroups of AML and outcome from high dose versus conventional dose ara-C as part of double induction therapy. Blood 1995;86:267a.
53. Mitus AJ, Miller KB, Schenkein DP, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995;13:560-9.
54. Evans C, Winkelstein A, Rosenfeld CS, Zeigler ZR, Shadduck RK. High-dose cytosine arabinoside and L-asparaginase therapy for poor-risk adult acute nonlymphoctyic leukemia. Cancer 1990;65:2624-30.
55. Preisler HD, Raza A, Barcos M, et al. High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup study. J Clin Oncol 1987;5:75-82.
56. Parikh P, Powles R, Treleaven J, et al. High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study. Br J Cancer 1990;62:830-3.
57. Willman C, Kopecky K, Weick J, None I, Some P. Biologic parameters that predict treatment response in de novo acute myeloid leukemia: CD34, but not multidrug resistance gene is associated with a decreased complete remission rate and CD34 patients more frequently achieve CR with high dose cytosine arabinoside. Proc ASCO 1992;11:262a.
58. WitteT, Suciu D, Peetermans M, Fenauz R Strijckmans P, Hayat M. Intensive chemotherapy for poor prognosis myelodysplasia and secondary acute myeloid leukemia following MDS of more than 6 months duration. Leukemia 1995;9:1805-11.
59. Longmore G, Guinan EC, Weinstein HJ, Gelber RD, Rappeport JM, Antin JH. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol 1990;8:1707-14.
60. Daenen S, Lowenberg B, Sonneveld P, et al. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Leukemia 1994;8:6-10.
61. Biggs JC, Horowitz MM, Gale RR et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992;80:1090-3.
62. Warrell RR Jr, DeThe H, Wang Z-Y, Degos L. Acute promyelocytic leukemia. N Engl JMedl993;329:177-89.
63. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995;85:2643-53.
64. Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994;83:10-25.
65. Rovelli A, Biondi A, Rajnoldi AC, et al. Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol 1992;10:1413-8.
66. Scott AA, Head DR, Kopecky K.J, et al. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia M3. Blood 1994;84:244-55.
67. Licht JD, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995;85:1083-94.
68. Warrell J, R.P. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood 1993;82:1949-53.
69. Castaigne S, Chomienne C, Daniel M-T, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704-9.
70. Meng-er H, Yu-chenY, Shu-rong C, et al. Use of all-transretinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
71. Pénaux R Le Deley MC, Castaigne S, et al. Effect of all-transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993;82:3241-9.
72. Tallman MS, Andersen J, Schiffer ÇA, et al. Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia (APL). Blood 1995;86:125a.
73. Fenaux P, Wattel E, Archimbaud E, et al. Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. Blood 1994;84:666-7.
74. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP, Jr.. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992;117:292-6.
75. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans-retinoic acid treatment of acute promyelocytic leukemia. Leukemia 1995;9:774-8.
76. Lo Coco F, Diverio D, Avvisati G, Luciano A, Biondi A, Mandelli F. High frequency of early molecular remission in acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (Italian GIMEMA-AIEOP"AlDA"Trial). Blood 1995;86:265a.
77. Chen Z-X, Xue Y-Q, Zhang R, et al. A clinical and experimental study on all-transretinoic acid-treated acute promyelocytic leukemia patients. Blood 1991 ;78:1413-9.
78. Head D, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995;86:1717-28.
79. Ohno R, Yoshida H, Fukutani H, et al. Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993;7:1722-7.
80. Cortes JE, Kantarjian H, O'Brien S, et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994;73:1946-52.
81. Degos L, Chomienne C, Daniel MT, et al.Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet 1990;336:1440-1.
82. Early E, Dmitrovsky E. Acute promyelocytic leukemia: retinoic acid response and resistance. J Invest Med 1995;43:337-44.
83. Taylor PRA, Reid MM, Stark AN, Bown N, Hamilton PJ, Proctor SJ. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Leukemia 1995;9:231 -7.
84. Johnson PRE, Hunt LP, LiuYin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol 1993;85:300-6.
85. Ferrara F, Mirto S. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukemia of the elderly. Br J Haematol 1996;92:627-31.
86. DeLima M, Ghaddar H, Pierce S, Esty E. Treatment of newly diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 1996;93:89-95.
87. Sebban C, Archimbaud E, Coiffier B, et al. Treatment of acute myeloid leukemia in elderly patients. Cancer 1988;61:227-31.
88. Willman CL. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1 ). Leukemia 1996;10S(l):S33-5.
89. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990;8:272-9.
90. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remissioninduction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268-74.
91. Kahn SB, Begg CB, Mazza JJ, Bennett JM, Bonner H, Click JH. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1984;2:865-70.
92. Foon KA, Zighelboim J, Yale C, Gale RP. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. Blood 1981 ;58:467-70.
93. Bigelow CL, Kopecky K, Files JC, et al. Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: A Southwest Oncology Group Study. Am J Hematol 1995;48:228-32.
94. Walters RS, Kantarjian HM, Keating MJ, Estey EH, McCredie KB, Freireich EJ. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer 1987;60:149-55.
95. BuchnerT, Hiddemann W, Loffler H, et al.Treatment ofAML in the elderly: full dose versus reduced dose induction treatment. Blood 1995;86:434a.
96. Mandelli F, Petti MC, ArdiaA, et al. A randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. EurJ Cancer 1991;27:750-5.
97. Arlin Z, Case DC, Jr., Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990;4:177-83.
98. Kahn SB, Ebrahim K, Cassileth RTooti F. Attenuated high-dose cytosine arabinoside in the treatment of the elderly patient with acute nonlymphocytic leukemia. Am J Clin Oncol 1989;12:201-8.
99. Petti MC, Mandelli F.Avvisati G,etal. High-dose ara-C (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the Italian cooperative group GIMEMA. EurJ Haematol 1989:42:24-31.
100. Frenette PS, Desforges JF, Schenkein DR Rabson A, Slapak C, Miller KB. Granulocytcmacrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia. Am J Hematol 1995:49:48-55.
101. Stone RM, Berg DT. George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients w ith primary acute myelogenous leukemia. N Engl.I Med 1995:332:1671-713.
102. Rowe JM, Andersen JW. Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (El490). Blood 1995:86:457-62.
103. Appelbaum FR. The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. CA Cancer.I Clin 1996:46:142-64.
104. Reiffers J, Gaspard MH, Maraninchi D, et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br J Haematol 1989:72:57-63.
105. Ferrant A, Doyen C, Delannoy A, et al. Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission. Bone Marrow Transplant 1991:7:303-9.
106. Eowcnbcrg B, Vcrdonck LJ, Dekker AW, et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J Clin Oneol 1990:8:287-94.
107. BurnettAK, GoldstoneAH, Stevens R F, et al.The role of BMT in addition to intensive chemotherapy inAML in first CR: results of the MRC AME-10 trial. Blood 1994;84:252a.
108. Harousseau JE. C'ahn JY. Pignon B. et al. Autologous bone marrow transplantation (ABMT) versus intensive consolidation chemotherapy (ICC) as post remission therapy in adult acute myeloblastic leukemia (AME): final analysis of the GOEEAM randomized study. ProcASCO 1996;15:358.
109. Zittoun R, Mandelli F,Willemze R,ctal. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995:332:217-24.
110. Zittoun R, Suciu S, SolbuG, et al. Comparison of quality of life (QOE) of patients with acute myelogenous leukemias (AME) in long-term first complete remission (CR) after bone marrow transplantation (BMT) allogeneic or autologous or intensive chemotherapy consolidation (ICC): EORTC-GIMEMAAME8Astudy. Blood 1995:86:433a.
111. Appelbaum FR. Fisher ED, Thomas ED, Team SMT. Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood 1988;72:179-84.
112. Frassoni F, Eabopin M, Gluckman E, et al. Are patients with acute leukaemia alive and well 2 years post bone marrow transplantation cured? A European study. Eeukemia 1994;8:924-8.
113. Ejungman P, De Witte T, Verdonck E, et al. Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Eeukaemia Working Party prospective analysis from HEA-typing. Br J Haematol 1993;84:61 -6.
114. Beatty PG, Clift RA, Miekelson EM.etal. Marrow transplantation from related donors otherthan HEA-identical siblings. N Engl.I Med 1985:313:765-71.
115. Ottinger H, Beelen D, Sayer H, Schaefer UW, Grosse-Wilde H. Bone marrow transplantation from partially HLA-matched related donors in adults with leukaemia: the experience at the University Hospital of Essen, Germany. Br J Haematol 1996;92:913-21.
116. Archimbaud E, Thomas X, Michallet M, et al. Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 1994;12:262-7.
117. Berman E, Little C, Gee T, O'Reilly R, Clarkson B. Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. N Engl JMed 1992;326:156-60.
118. Bearman SI, Mori M, Beatty PG, et al. Comparison of morbidity and mortality after marrow transplantation from HLA-genotypically identical siblings and HLA-phenotypically identical unrelated donors. Bone Marrow Transplant 1994;13:31-5.
119. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hématologie malignancies. Transplantation 1991;51:443-7.
120. Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donors for treatment of hématologie malignancies: effect of mismatching for one HLA locus. Blood 1993;81:249-53.
121. Cassileth PA, Andersen J, Lazarus HM, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 1993;11:314-9.
122. Korbling M, FliednerTM, Holle R, et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and diseasefree survival. Bone Marrow Transplant 1991;7:343-9.
123. TallmanMS, Kopecky KJ, Amos D, et al. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. J Clin Oncol 1989;7:326-37.
124. Perkins HA, Kollman C, Howe CWS. Unrelated-donor marrow transplants: the experience of the National Marrow Donor Program. Clin Transpl 1994:295-301.
125. Gale RP, Horowitz MM, Weiner RS, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995;16:203-8.
126. Imrie K, Prince HM, Dube I, Crump M, Stewart AK, KeatingA. Malignant karyotype predicts outcome after but not before autologous bone marrow transplantation (ABMT) in transplant candidates with acute myeloid leukemia (AML). Blood 1995;86:42a.
127. Mehta J, Powles R, Singhal S, et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995;16:499-506.
128. Sierra J, GranenaA, Garcia J, et al. Autologous bone marrow transplantation for acute leukemia: results and prognostic factors in 90 consecutive patients. Bone Marrow Transplant 1993;12:517-23.
129. Brown RA, Herzig RH,Wolff SM, et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hématologie malignancy. Blood 1990;76:473-9.
130. Schiller GJ, Nimer SD, Territo MC, Ho WG, Cahmplin RE, Gajewski JL. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992;10:41 -6.
131. Schiller G, Gajewski J, Territo M, et al. Long-term outcome of high-dose cytarabinebased consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992;80:2977-82.
132. Cassileth PA, Begg CB, Silber R, et al. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. Cancer Treat Rep 1987;71:137-40.
133. BuchnerT, Hiddemann W, Loffler G, et al. Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group. SeminHematol 1991;28:76-9.
134. Rohatiner AZS, Bassan R, Battista R, et al. High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukemia. Br J Cancer 1990;62:454-8.
135. Hussein KK, Dahlberg S, Head D, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989;73:57-63.
136. Linker CA, Levitt LJ, O'Donnell M, Forman SJ, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991;78:2814-22.
137. Wiernik PH, Dutcher JP, Paietta E, et al. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen. Leukemia 1993;7:1236-41.
138. Mandelli F, Annino L,VegnaML, étal. GIMEMA ALL 0288: a multicentric study on adult acute lymphoblastic leukemia. Preliminary results. Leukemia 1992;6:182-5.
139. Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 1990;8:994-1004.
140. Kantarjian H, O'Brien S, Beran M, et al. Update of the hyper-CVAD program in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 1995;86:173a.
141. Radford J, Burns C, Jones M, Gingrich R, Kemp J. Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protocol. J Clin Oncol 1989;7:58-66.
142. Gottlieb AJ, WeinberV, Ellison RR, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood 1984;64:267-74.
143. Weiss M,Telford P, Kempin S, et al. Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia. Leukemia 1993;7:832-7.
144. Ottmann OG, Hoelzer D, Gracien E, et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995;86:444-50.
145. Ellison RR, Mick R, Cuttner J, et al. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol 1991;9:2002-15.
146. Cuttner J, Mick R, Budman DR, et al. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB study. Leukemia 1991;5:425-31.
147. Omura GA, Moffitt S, Vogler WR, Salter MM. Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 1980;55:199-204.
148. Cortes J. O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995;86:2091-7.
149. Horowitz M, Messerer D, Hoelzer D, Nonsense P, Some P. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission.Ann Intern Med 1991;115:13-8.
150. Attal M, Biaise D, Mark G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood
151. Westbrook ÇA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study (8762). Blood 1992;80:2983-90.
152. Chao NJ, Blume KG, Forman SJ, Snyder DS. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995;85:3353-4.
153. BarrettAJ, Horowitz MM, Ash RC. et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992;79:3067-70.
154. Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pédiatrie protocols. Blood 1995;85:664-74.
155. HoelzerD, Ludwig W-D,ThielE, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996;87:495-508.
156. Taylor PRA, Reid MM, Bown N, Hamilton PJ, Proctor SJ. Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood 1992;80:1813-7.
157. FerrariA,Annino L, Crescenzi S, Romani C, Mandelli F. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25year period. Leukemia 1995;9:1643-7.
158. Peterson BA, Brunning RD, Bloomfield CD, et al. Central nervous system involvement in acute nonlymphocytic leukemia: a prospective study of adults in remission. Am J Med 1987;83.
159. Morra E, Lazzarino M, Brusamolino E, et al. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Cancer 1993;72:439-45.
160. Davis CL, RohatinerAZS, Lim J, et al.The management of recurrent acute myelogenous leukaemia at a single centre over a lifteen-year period. BrJ Haematol 1993;83:404-l 1.
161. Freund M, Diedrich H, Ganser A, et al.Treatment of relapsed or refractory adult acute lymphocytic leukemia. Cancer 1992;69:709-16.
162. Giona F, Testi AM, Annino L, et al.Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Br J Haematol 1994;86:55-61.
163. Kantarjian HM, Estey E, O'Brien S, étal. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Cancer 1993;72:2950-5.
164. Peterson BA, George SL, Bhalla K, et al. A phase III trial with or without GM-CSF administered before and during high dose cytarabine in patients with relapsed or refractory acute myelogenous leukemia. ProcASCO 1996;15:26.
165. Estey EH. Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 1994;83:2015-9.
166. Ohno R, NaoeT, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994;83:2086-92.
167. Hiddemann W, Martin W-R, Sauerland C-M, Heinecke A, Buchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990;4:184-8.
168. Keating MJ, Kantarjian H, Smith TL, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989;7:1071-80.
169. Uhlman DL, Bloomfield CD, Hurd DD, Peterson BA. Prognostic factors at relapse for adults with acute myeloid leukemia. Am JHematol 1990;33:110-6.
170. Estey F. Keating MJ, Pierce S, Stass S. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia 1995;9:972-6.
171. Schiller G. Treatment of resistant acute myeloid leukemia. Blood Rev 1991;5:220-6.
172. Gale RP. Horowitz MM, Rees JK.H, et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 1996;10:13-9.
173. Doney K., Fisher LD, Appelbaum FR. et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991:7:453-9.
174. Wingard JR, Piantadosi S, Santos GW, et al. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia.,1 ClinOncol 1990;8:820-30.
175. BarrettAJ, Horowitz MM, Gale RP, etal. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989:74:862-71.
176. Brown RA, Wolff SN. Fay JW. et al. High-dose etoposidc, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group. Blood 1995:85:1391-5.
177. Clift RA, Buckner CD, Appelbaum FR. et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992:10:1723-9.
178. Doney K, Buckner CD, Fisher L, et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant 1993:12:315-21.
179. BuscaA, Anasetti C.Anderson G, etal. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood 1994:83:3077-84.
180. Chopra R, GoldstoneAH, McMillan AK, et al. Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: The BritishAutograft Group Experience. J Clin Oncol 1991:9:1840-7.
181. Schiffman K, Clift R, Appelbaum FR, et al. Consequences of cryopreserving first remission autologous marrow for use after relapse in patients with acute myeloid leukemia. Bone Marrow Transplant 1993:11:227-32.
182. Petersen FB, Lynch MHE, Clift RA, et al. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 1993;11:1353-60.
183. Gorin NC, Labopin M, Meloni G, et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging bymafbsfamidc. Leukemia 1991:5:896-904.
184. Yeager AM, Kaizer H, Santos GW. et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4hydroperoxycyclophosphamide. N Engl J Med 1986:315:141-7.
185. Demirer T, Buckner CD, Appelbaum FR, et al. Rapid engraftment after autologous transplantation utilizing marrow and rccombinant granulocytc colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia. Bone Marrow Transplant 1995:15:915-22.
186. Borgmann A, Schmid H, Hartmann R, et al. Autologous bone marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-pair analysis. Lancet 1995:346:873-6.
187. Barren AJ, Horowitz MM, Pollock BH. et al. Bone marrow transplants from HLAidentical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994:331:1253-8.
188. Soiffer RJ, Roy DC, Gonin R, et al. Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant 1992;12:243-51.
189. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983;62:361-9.
190. Kantarjian HM, Estey EH, Plunkett W, et al. Phase I-II clinical and pharmacologie studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 1986;81:387-94.
191. Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991 ;9:1210-4.
192. Feldman EJ, Alberts DS, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993;11:2002-9.
193. CarellaAM, Carlier P, Pungolino E, et al. Idarubicin in combination with intermediatedose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 1993;7:196-9.
194. Capizzi RL, Poole M, Cooper MR, et al. Treatment of poor risk acute leukemia with sequential high-dose ara-C and asparaginase. Blood 1984;63:694-700.
195. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapyresistance modifier in acute leukemia. J Clin Oncol 1993;11:1652-60.
196. Solary E, Caillot D, Chauffert B, et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 1992;10:1730-6.
197. Archimbaud E,ThomasX, LeblondY et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995;13:11 -8.
198. Kantarjian HM, Estey EH, O'Brien S, et al. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood 1992;79:876-81.
199. Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993;11:304-13.
200. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996;87:2195-204.